Becton, Dickinson and Company $BDX Shares Acquired by Forsta AP Fonden

by · The Cerbat Gem

Forsta AP Fonden increased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 9.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,400 shares of the medical instruments supplier’s stock after purchasing an additional 5,400 shares during the period. Forsta AP Fonden’s holdings in Becton, Dickinson and Company were worth $10,404,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. FORA Capital LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $3,458,000. RiverGlades Family Offices LLC acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth $344,000. Versor Investments LP raised its position in shares of Becton, Dickinson and Company by 73.2% during the second quarter. Versor Investments LP now owns 4,336 shares of the medical instruments supplier’s stock worth $747,000 after purchasing an additional 1,833 shares during the period. Finally, Hutchinson Financial Advisors INC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at $1,024,000. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,249 shares of company stock worth $231,358 in the last 90 days. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Up 0.5%

NYSE BDX opened at $193.03 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The firm’s fifty day simple moving average is $186.65 and its 200-day simple moving average is $182.03. The company has a market capitalization of $55.33 billion, a PE ratio of 34.72, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BDX. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Stifel Nicolaus lowered their price objective on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $203.27.

Check Out Our Latest Stock Analysis on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).